Drug Approval | May 20, 2023
Strides Puducherry facility receives EIR from USFDA
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
The USFDA had classified Strides Puducherry facility as OAI in May 2019 followed by issuing a warning letter to this site in July 2019.
To enhance housing and enclosure design and performance for the Asia Pacific medical devices market, Kraiburg TPE offers the Thermoplast H HC/AP and HC/AD1/AP series
The facility will have a capacity to manufacture upto 3 million tubes monthly
Cipla has reported total income of Rs. 5873.93 crores during the period ended March 31, 2023
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Pheezee is designed to assess musculoskeletal and neuromuscular health.
The partnership will commercialize four nasal sprays with a combined Global IQVIA market size in excess of $400m
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
China recorded unprecedented improvement in its API manufacturing score in the 2022 end of year CPHI Survey
Specialty Chemicals grew 38% YoY for FY23
Subscribe To Our Newsletter & Stay Updated
